Wells Fargo & Company MN boosted its holdings in shares of Qiagen NV (NASDAQ:QGEN) by 12.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 86,594 shares of the company’s stock after purchasing an additional 9,864 shares during the quarter. Wells Fargo & Company MN’s holdings in Qiagen were worth $2,727,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Oppenheimer Asset Management Inc. increased its position in shares of Qiagen by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after purchasing an additional 20 shares during the last quarter. M&T Bank Corp increased its position in shares of Qiagen by 2.7% during the 2nd quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock valued at $273,000 after purchasing an additional 215 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Qiagen by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after purchasing an additional 225 shares during the last quarter. QS Investors LLC increased its position in shares of Qiagen by 1.7% during the 2nd quarter. QS Investors LLC now owns 13,594 shares of the company’s stock valued at $456,000 after purchasing an additional 226 shares during the last quarter. Finally, Acrospire Investment Management LLC boosted its holdings in Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after acquiring an additional 349 shares during the period. 62.09% of the stock is currently owned by institutional investors.
A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Evercore ISI began coverage on Qiagen in a report on Wednesday, January 3rd. They set an “outperform” rating and a $35.00 price objective for the company. Morgan Stanley upped their target price on Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday. BidaskClub upgraded Qiagen from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, Goldman Sachs Group began coverage on Qiagen in a report on Monday, January 29th. They issued a “buy” rating and a $39.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $35.33.
Shares of Qiagen NV (QGEN) traded down $0.66 on Friday, hitting $33.34. The stock had a trading volume of 1,388,287 shares, compared to its average volume of 1,240,000. Qiagen NV has a 1 year low of $27.74 and a 1 year high of $36.34. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $7,700.00, a P/E ratio of 85.49, a price-to-earnings-growth ratio of 2.01 and a beta of 1.03.
Qiagen (NASDAQ:QGEN) last issued its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. The firm had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 earnings per share. equities research analysts expect that Qiagen NV will post 1.25 EPS for the current fiscal year.
Qiagen declared that its Board of Directors has initiated a share repurchase program on Wednesday, January 31st that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Grows Stake in Qiagen NV (NASDAQ:QGEN)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/wells-fargo-company-mn-purchases-9864-shares-of-qiagen-nv-qgen.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.